03:03 , Jan 26, 2019 |  BioCentury  |  Product Development

Target wide, test narrow in lupus

While last year’s spate of clinical misses in lupus leave the field still in search of optimal targets, the 2019 outlook isn’t all doom. Companies with shots on goal are using sharper endpoints and aiming...
19:35 , Jan 24, 2019 |  BC Innovations  |  Emerging Company Profile

Cabaletta’s CAAR Ts for autoimmunity

Cabaletta Bio Inc.’s CAAR T therapy is geared to treat B cell-mediated autoimmunity without wiping out all B cells. The company is betting an antigen-specific approach will yield efficacy without CARs’ safety drawbacks. Cabaletta spun...
19:38 , Jan 16, 2019 |  BC Innovations  |  Distillery Therapeutics

Autoimmune disease

INDICATION: Multiple sclerosis (MS) Patient sample and mouse studies suggest adoptive transfer, or promoting the survival, of IgA-positive plasmablasts and plasma cells could help treat MS. In fecal samples from relapsing-remitting MS (RRMS) patients, counts...
19:37 , Jan 16, 2019 |  BC Innovations  |  Translation in Brief

Promoting gut plasmablasts for MS

Researchers from the University of Toronto and colleagues have linked the gut-brain axis to multiple sclerosis by showing gut plasmablasts and plasma cells suppress CNS inflammation during active MS, and suggested therapies that promote the...
16:41 , Sep 7, 2018 |  BC Week In Review  |  Clinical News

AZ's anifrolumab misses in Phase III for lupus

AstraZeneca plc (LSE:AZN; NYSE:AZN) and its MedImmune LLC unit said anifrolumab (formerly MEDI-546) missed the primary endpoint in the Phase III TULIP 1 trial to treat systemic lupus erythematosus (SLE). Compared with placebo, anifrolumab failed...
18:15 , Aug 31, 2018 |  BC Extra  |  Clinical News

AZ's anifrolumab misses in Phase III for lupus

AstraZeneca plc (LSE:AZN; NYSE:AZN) and its MedImmune LLC unit said anifrolumab (formerly MEDI-546) missed the primary endpoint in the Phase III TULIP 1 trial to treat systemic lupus erythematosus (SLE). Compared with placebo, anifrolumab failed...
16:43 , Jul 6, 2018 |  BC Week In Review  |  Clinical News

Neovacs planning Phase III for lupus therapy on mixed Phase IIb data

Neovacs S.A. (Euronext:ALNEV) plans to start Phase III testing of lupus candidate IFNalpha-Kinoid despite reporting mixed data from a Phase IIb trial in the indication. IFNalpha-Kinoid is an immunotherapy against interferon (IFN) alpha. The therapy...
15:05 , Jul 3, 2018 |  BC Extra  |  Clinical News

Neovacs planning Phase III for lupus therapy on mixed Phase IIb data

Neovacs S.A. (Euronext:ALNEV) plans to start Phase III testing of lupus candidate IFNalpha-Kinoid despite reporting mixed data from a Phase IIb trial in the indication on Tuesday. IFNalpha-Kinoid is an immunotherapy against interferon (IFN) alpha....
01:10 , Aug 11, 2017 |  BC Innovations  |  Strategy

The flip-side of immunotherapy

In the smaller print of last week’s deal between IFM Therapeutics Inc. and Bristol-Myers Squibb Co. was the latest example of a growing trend of companies aiming to draw extra value out of a cancer...
23:50 , Jul 27, 2017 |  BC Week In Review  |  Clinical News

FDA approves GSK's subcutaneous Benlysta for SLE

FDA approved subcutaneous Benlysta belimumab from GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) to treat systemic lupus erythematosus (SLE). GSK said the human mAb against BLyS ( BAFF ; TNFSF13B) is the first subcutaneous, self-injectable therapy that FDA...